Log in

Relevant bibliographies by topics / Buprenorphine buccal film

Contents

Journal articles

Academic literature on the topic 'Buprenorphine buccal film'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Buprenorphine buccal film.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Buprenorphine buccal film"

1

Hale, Martin, Joseph Gimbel, and Richard Rauck. "Buprenorphine buccal film for chronic pain management." Pain Management 10, no. 4 (2020): 213–23. http://dx.doi.org/10.2217/pmt-2020-0013.

Full text

Abstract:

Buprenorphine is a Schedule III opioid with unique pharmacodynamic and pharmacokinetic properties that contribute to effective analgesia and fewer safety risks than other opioids. This review article focuses on the buccal film formulation, which is preferable to other buprenorphine formulations on the basis of bioavailability, safety and efficacy. The clinical studies reviewed here confirm that buprenorphine buccal film offers effective and continuous pain relief that is generally well tolerated, with no cases of respiratory depression reported in any of the studies. On the basis of these clin

APA, Harvard, Vancouver, ISO, and other styles

2

Jackson, Leanne K., Ivy O. Poon, Mary A. Garcia, Syed Imam, and Ursula K. Braun. "Buprenorphine Use for Analgesia in Palliative Care." Pharmacy 12, no. 3 (2024): 78. http://dx.doi.org/10.3390/pharmacy12030078.

Full text

Abstract:

Buprenorphine is a semi-synthetic long-acting partial µ-opioid receptor (MOR) agonist that can be used for chronic pain as a sublingual tablet, transdermal patch (Butrans®), or a buccal film (Belbuca®). Buprenorphine’s unique high receptor binding affinity and slow dissociation at the MOR allow for effective analgesia while offering less adverse effects compared to a full agonist opioid, in particular, less concern for respiratory depression and constipation. It is underused in chronic pain and palliative care due to misconceptions and stigma from its use in opioid use disorder (OUD). This cas

APA, Harvard, Vancouver, ISO, and other styles

3

Zimmerman, Amanda. "Conversion of CII Opioid Medications to Buprenorphine in the Chronic Pain Population - Insights and Clinical Pearls." Journal of Opioid Management 20, no. 4 (2024): B11. http://dx.doi.org/10.5055/bupe.24.rpj.1060.

Full text

Abstract:

Background: There is a great deal of confusion associated with conversion from CII opioid to buprenorphine products. The data presented supports that patients can be converted from high dose opioid medication to buprenorphine products safely and effectively. This presentation will provide a road map to help guide practitioners who are interested in applying this to their clinical practice. Purpose/hypothesis: The purpose of the research was not only to discover if conversion to a partial agonist CIII medication from full agonist CII medications would be achieveable without sacrificing analgesi

APA, Harvard, Vancouver, ISO, and other styles

4

Soyka, Michael. "Buprenorphine–naloxone buccal soluble film for the treatment of opioid dependence: current update." Expert Opinion on Drug Delivery 12, no. 2 (2014): 339–47. http://dx.doi.org/10.1517/17425247.2014.953479.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Webster, MD, Lynn, Jacqueline Cater, PhD, and Thomas Smith, MD. "Effects of buprenorphine buccal film and oral oxycodone on pupil diameter in a respiratory study." Journal of Opioid Management 18, no. 2 (2022): 181–90. http://dx.doi.org/10.5055/jom.2022.0708.

Full text

Abstract:

Objective: Evaluate the pupillary-constricting effects following administration of buprenorphine buccal film (BBF) and immediate-release (IR) oxycodone.Design: A double-blind, double-dummy, six-treatment, six-period, placebo-controlled, randomized crossover study.Setting: Single-center, phase 1 exploratory pharmacodynamics.Participants: Healthy individuals who self-identify as recreational opioid users, confirmed via a naloxone challenge test on day 1.Interventions: Placebo: BBF 300, 600, and 900 mcg and IR oxycodone 30 and 60 mg.Main outcome measure: Minute ventilation (measured by the ventil

APA, Harvard, Vancouver, ISO, and other styles

6

Webster, Lynn, Jacqueline Cater, and Thomas Smith. "Risk Stratification of Respiratory Depression with Buprenorphine Buccal Film Versus Oxycodone: Phase 1 Trial Outcomes." Pain Management Nursing 23, no. 2 (2022): 247–48. http://dx.doi.org/10.1016/j.pmn.2022.02.065.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Webster, Lynn, Jacqueline Cater, and Thomas Smith. "Buprenorphine Buccal Film Versus Oxycodone: Pupillometry and Respiratory Depression Effects in a Phase 1 Trial." Pain Management Nursing 23, no. 2 (2022): 248. http://dx.doi.org/10.1016/j.pmn.2022.02.066.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Webster, Lynn, Jacqueline Cater, and Thomas Smith. "Buprenorphine Buccal Film Versus Oxycodone: Respiratory, Pharmacokinetic, and Pupillometry Outcomes from a Phase 1 Trial." Pain Management Nursing 23, no. 2 (2022): 247. http://dx.doi.org/10.1016/j.pmn.2022.02.064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Bai, Stephen A., Qinfang Xiang, and Andrew Finn. "Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers." Clinical Therapeutics 38, no. 2 (2016): 358–69. http://dx.doi.org/10.1016/j.clinthera.2015.12.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Webster, MD, Lynn, and Richard L. Rauck, MD. "Atypical opioids and their effect on respiratory drive." Journal of Opioid Management 17, no. 7 (2021): 109–18. http://dx.doi.org/10.5055/jom.2021.0648.

Full text

Abstract:

Opioids are an important tool in the treatment of pain, but opioid overdose has become a serious health issue. Most opioid-related deaths are caused by respiratory depression, and the risk of respiratory depression is compounded because of the risks of abuse and diversion, which makes the need for safer opioids even more urgent. However, the atypical opioids (buprenorphine, tramadol, and tapentadol), with mechanisms of action not purely driven by μ-opioid receptor agonism, may be safer than conventional opioids, eg, morphine, oxycodone, and fentanyl. The purpose of this narrative review is to

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!